TED

Dr. Jeannelle Perkins-Muhammad, Noted Relationships Expert on Racism's Impact on Black Intimacy, to be a Featured Speaker at TEDxCharleston 2024

Retrieved on: 
Tuesday, April 9, 2024
Racism, TED (conference), Drainage, Marriage, Liberty, Family therapy, The Post and Courier, Education, Post, TED, Mental health, Doctor of Philosophy, Divorce, Nursing

CHARLESTON, S.C., April 9, 2024 /PRNewswire-PRWeb/ -- Dr. Jeannelle Perkins-Muhammad, international speaker and author, will illuminate the TEDxCharleston 2024 stage on April 17 at the Charleston Music Hall from 12:30 - 5PM. The independently organized event, licensed by TED, will feature local voices, performers and TED Talks videos under the theme "Uncharted." Dr. Jeannelle will speak on how racism negatively impacts the emotional and mental health of Black couples.

Key Points: 
  • CHARLESTON, S.C., April 9, 2024 /PRNewswire-PRWeb/ -- Dr. Jeannelle Perkins-Muhammad, international speaker and author, will illuminate the TEDxCharleston 2024 stage on April 17 at the Charleston Music Hall from 12:30 - 5PM.
  • The independently organized event, licensed by TED, will feature local voices, performers and TED Talks videos under the theme "Uncharted."
  • Dr. Jeannelle will speak on how racism negatively impacts the emotional and mental health of Black couples.
  • For more information about TEDxCharleston and to buy tickets, please visit https://tedxcharleston.org/ or contact the Charleston Music Hall box office at 843-853-2252.

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

Retrieved on: 
Wednesday, March 20, 2024
Oculoplastics, Patient, Private practice, Webcast, TED, Cohort, Standard of care, NEJM, MD, Graves' ophthalmopathy, Hyperglycemia, Safety, Huber loss, Orbital, Medical device

LOS ANGELES, March 20, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a validated mechanism of action for the treatment for TED.

Key Points: 
  • There have been no reports of hyperglycemia or hearing impairment and no serious adverse events.
  • “It is very encouraging to see the results of subcutaneous administration of an anti-IGF-1R therapy.
  • The data shown suggest that there is a clinically meaningful response in patients as early as 3 weeks after a single subcutaneous dose of lonigutamab.
  • “It is important to note that this is preliminary data in a small group, however the positive results are highly promising.

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Wednesday, March 20, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Research, Multiple myeloma, Lung cancer, Partner, NMPA, Growth, NSCLC, CIDP, Partnership, Telephone, GSK, Patient, TED, NASDAQ Biotechnology Index, Epitope, Artificial intelligence, Sale, Myasthenia gravis, Neonatal Fc receptor, Fluorouracil, Graves' ophthalmopathy, Investment, Teclistamab, NBI, National Medical Products Administration, Johnson & Johnson, Drug development, Safety, Chicken, Machine learning, Gastrointestinal cancer, Immunoglobulin G, BLA, Chronic inflammatory demyelinating polyneuropathy, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
  • OmniAb launched two new technologies during 2023 including OmniDeep™ and, during the fourth quarter, OmnidAb™.
  • Fourth quarter 2023 and recent partner highlights include the following:
    Immunovant reported positive initial results for batoclimab in Graves’ disease (GD).
  • OmniAb was added to the Nasdaq Biotechnology Index (NBI) in the fourth quarter.

Brené Brown and Mindy Kaling Join Tracee Ellis Ross, Adam Grant, James Clear at BetterUp’s Uplift

Retrieved on: 
Monday, March 11, 2024
Thought Leadership, Human Resources, General Health, Health, Mental Health, Professional Services, Business, Other Health, Uncertainty, Culture, Organization, Growth, Learning, The New York Times, Beauty, Thought, Empathy, TED, Knowledge, Research, Lead, Courage, Human, Perseverance, United States Air Force, NASA, Cisco, Hospital, Daring Greatly, Employment, Creativity, Multimedia, Workplace, Duke, Management

The immersive summit will feature the exchange of ideas and inspirational conversations delivering unparalleled insights around leadership, talent retention, growth, and performance.

Key Points: 
  • The immersive summit will feature the exchange of ideas and inspirational conversations delivering unparalleled insights around leadership, talent retention, growth, and performance.
  • Brené Brown will also join the stage and speak about her expertise on courageous leadership in today’s world with BetterUp CEO & Co-founder Alexi Robichaux.
  • Brené has transformed our understanding of leadership, empathy, and the strength found in vulnerability through her groundbreaking work.
  • Tickets for Uplift are available for purchase and anyone can tune into the event via a free live stream.

GLOBAL CITIZEN NOW RETURNS TO NEW YORK WITH PAUL KAGAME, PRESIDENT OF RWANDA, MOKGWEETSI MASISI, PRESIDENT OF BOTSWANA, GASTON BROWNE, PRIME MINISTER OF ANTIGUA AND BARBUDA, PHILIP DAVIS, PRIME MINISTER OF THE BAHAMAS, JANJA LULA DA SILVA, THE FIRST LADY

Retrieved on: 
Thursday, March 28, 2024
International Labour Organization, Human rights, United Nations, TriBeCa Productions, P&G, Vaccine, Policy, Courage, Gender, First lady, Authentic Brands Group, Education, TED, SVP, Economic development, Communication, Global Citizen, Jeff Bezos, PayPal, Global Citizen Prize, Ford Foundation, Ford, Climate change, Woman, EVP, Citizenship, Public policy, Food, Private sector, Poverty, Guardian, Rockefeller Foundation, Senait Fisseha, Health, Consumer, Bridgewater Associates, Buffett Foundation, Former, UN Women Goodwill Ambassador, CVC Capital Partners, Delta Air Lines, UN, Management

NEW YORK, March 28, 2024 /PRNewswire/ -- Global Citizen NOW, the summit driving action to end extreme poverty, returns to New York City for a third year, on May 1 and 2. Leaders from the worlds of public policy, media, entertainment, philanthropy, advocacy, and the private sector will convene for two dynamic days focused on taking action today to save tomorrow. 

Key Points: 
  • Global Citizen NOW co-chairs include long-time Global Citizen supporters Anitta, Danai Gurira, Hugh Jackman, Dakota Johnson, and Michelle Yeoh.
  • Political leaders co-chairing this year's summit include Paul Kagame, President of Rwanda; Mokgweetsi Masisi, President of Botswana; Gaston Browne, Prime Minister of Antigua and Barbuda; Philip Davis, Prime Minister of the Bahamas; Stefan Löfven, Former Prime Minister of Sweden; and Erna Solberg, Former Prime Minister of Norway.
  • Global Citizen NOW returns this May with a powerful two-day program focused on turning ideas into actionable impact to end extreme poverty NOW.
  • Applications are now open for media outlets to attend and cover Global Citizen NOW and Global Citizen Prize at Spring Studios in New York City May 1-2.

The Progeria Research Foundation Selected as an Official Charity Partner in 2024 Boston Marathon

Retrieved on: 
Tuesday, March 26, 2024
Research, Friends, Disease, Emmy Awards, Memory, Partnership, TED, Boston Athletic Association, PRF, Bank, Attitude, Progeria Research Foundation, Athlete, Boston Marathon, Thought, DRS, HBO, FDA, TED (conference), Parent, Boston, Boylston Street

PEABODY, Mass., March 26, 2024 /PRNewswire/ -- The Progeria Research Foundation (PRF), the only nonprofit solely dedicated to finding treatments and the cure for Progeria, celebrates its first year as an Official Charity Partner of the Boston Athletic Association's 128th Bank of America Boston Marathon®. Represented by a team of 10 passionate runners, this partnership will bring vital funds for Progeria research endeavors, while casting a light on this ultra-rare disease and PRF's progress toward the cure.

Key Points: 
  • PRF's 10 Marathon Runners Raise Funds to cure Progeria, all connected to Sam Berns
    PEABODY, Mass., March 26, 2024 /PRNewswire/ -- The Progeria Research Foundation (PRF), the only nonprofit solely dedicated to finding treatments and the cure for Progeria, celebrates its first year as an Official Charity Partner of the Boston Athletic Association's 128th Bank of America Boston Marathon®.
  • Without treatment, children with Progeria die of heart disease at an average age of 14.5 years old.
  • "From Foxboro neighbors, to middle school classmates, to athletes who got to know Sam at PRF's annual 5K Race for Research – it's heartwarming to know they're now representing The Progeria Research Foundation at the Boston Marathon, in Sam's honor."
  • "This is a tremendous honor to be invited to join the Bank of America's Official Charity Program in the 2024 Boston Marathon," said Audrey Gordon, President and Executive Director of The Progeria Research Foundation.

JOURNAL OF ORTHOPEDICS STUDY REVEALS BENEFIT OF INCREDIWEAR AFTER TOTAL KNEE ARTHROPLASTY

Retrieved on: 
Tuesday, March 12, 2024
Temperature, TKA, Surgeon, Germanium, Patient, TED, Journal, Motion, Overalls, Carbon, Patient satisfaction, Brace, Pain management, Clutch (eggs), Pain, PTS, Surgery, Swelling, PubMed, Medical device

CHICO, Calif., March 12, 2024 /PRNewswire/ -- The Journal of Orthopedics published the results of a study concluding that Incrediwear, the leading provider of innovative therapeutic wear, provides more benefit after total knee arthroplasty (TKA) than compression stockings or Thrombo-Embolsim Deterrent (TED) Hose, routinely prescribed after TKA. The study, "Noncompressive sleeves versus compression stockings after total knee arthroplasty: A prospective pilot study," aimed to compare the efficacy of non-compressive sleeves versus compression stockings for postoperative recovery in TKA patients.

Key Points: 
  • CHICO, Calif., March 12, 2024 /PRNewswire/ -- The Journal of Orthopedics published the results of a study concluding that Incrediwear , the leading provider of innovative therapeutic wear, provides more benefit after total knee arthroplasty (TKA) than compression stockings or Thrombo-Embolsim Deterrent (TED) Hose, routinely prescribed after TKA.
  • The study, "Noncompressive sleeves versus compression stockings after total knee arthroplasty: A prospective pilot study," aimed to compare the efficacy of non-compressive sleeves versus compression stockings for postoperative recovery in TKA patients.
  • The prospective pilot study involved a sample size of 55 TKA patients assigned to either the non-compressive Incrediwear sleeve group or the compression stocking group.
  • To be recognized by the prestigious Journal of Orthopedics further reinforces that medical professionals should be using Incrediwear for anyone undergoing total knee arthroplasty."

Rokid Will Release a New AR Consumer-Grade Product Based on Spatial Computing

Retrieved on: 
Thursday, February 22, 2024
TED, Amblyopia, FOV, Natural language processing, IPhone, IOS, Black Friday, AI, Smartglasses, Education, Telehealth, 3D, Sale, App, Apple TV, Google Play, University, Android, Patient, Teaching, Knowledge, Gesture, Amazon, OST, Museum, Mobile phone

New York, New York--(Newsfile Corp. - February 22, 2024) - In March 2024, Rokid will release a new AR consumer-grade product based on spatial computing, which is lighter in weight and fully supports 3D content, spatial interaction and 4K high-definition video.

Key Points: 
  • New York, New York--(Newsfile Corp. - February 22, 2024) - In March 2024, Rokid will release a new AR consumer-grade product based on spatial computing, which is lighter in weight and fully supports 3D content, spatial interaction and 4K high-definition video.
  • Weighing only 76 grams, Rokid Max Pro has the spatial interaction capabilities such as gestures and sounds.
  • Fully adapting Google android TV makes Rokid Station becoming the first AR version of the portable Android TV terminal, and inducts Google Play.
  • Rokid Max AR Glasses have excellent configuration including 120HZ refresh rate, 50-degree FOV large viewing angle, and 0-600 degree refractive adjustment.

MethaneSAT Now in Orbit after SpaceX Launches Groundbreaking Mission to Protect the Climate

Retrieved on: 
Tuesday, March 5, 2024
Technology, Aerospace, Manufacturing, Oil, Gas, Military, Environmental Issues, Environmental Health, Energy, Defense, Environment, Sustainability, Green Technology, Satellite, Climate Change, New Zealand Space Agency, Ball, System, Climate change, Legislation, EPA, Map, Methane, Google Earth, TED, Jeff Bezos, EDF, Energy transition, European, Bloomberg L.P., Space, Bloomberg Philanthropies, Economics, Agriculture, TED (conference), Partnership, Arnold Ventures LLC, Multimedia, Diplomatic rank, All rights reserved, Applied science, International Energy Agency, RMI, COP, Krupp, SpaceX, Environmental Defense Fund, UN, Ball Aerospace & Technologies, Bloomberg, Analytics, BAE Systems, Government, Policy, MethaneSAT

Just after 4:00pm Pacific Time today MethaneSAT effectively detached from SpaceX Transporter-10 that carried the emissions monitor into space.

Key Points: 
  • Just after 4:00pm Pacific Time today MethaneSAT effectively detached from SpaceX Transporter-10 that carried the emissions monitor into space.
  • The groundbreaking satellite is designed to help protect the Earth’s climate by accelerating reductions of a powerful greenhouse pollutant, focusing first on oil and gas operations, a major source of methane.
  • MethaneSAT will show us the full scope of the opportunity by tracking emissions to their source.”
    Krupp announced MethaneSAT in a 2018 TED Talk as part of the TED Audacious Project .
  • MethaneSAT was made possible entirely by the support of EDF donors and our partnership with the Government of New Zealand .

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, TED, Neonatal Fc receptor, Research, Accounting, Investment, Safety, ATM, Sale, Graves' ophthalmopathy, Immunoglobulin G, Therapy, Abstract, Patient, Half-life, IND, Trial of the century, Bank statement, Pharmaceutical industry

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • “Throughout 2023, we delivered important clinical results across our TED portfolio, marking significant progress for the company,” said Steve Mahoney, Viridian President and Chief Executive Officer.
  • Two ongoing registrational Phase 3 clinical trials, THRIVE and THRIVE-2, are continuing to enroll patients with active and chronic TED, respectively.
  • In October 2023, Viridian unveiled its development of a portfolio of engineered FcRn inhibitors, including VRDN-006 and VRDN-008.